Development and in vitro evaluation of solid dispersions as strategy to improve albendazole biopharmaceutical behavior

SIMONAZZI, A.; CID, A.G.; PAREDES, A.J.; SCHOFS, L.; GONZO, E. E.; PALMA, S.D.; BERMÚDEZ, J.M.

Therapeutic Delivery

Future Science

Lugar: London; Año: 2018 vol. 9 p. 623 - 638

2041-5990

Aim: Solid dispersions using Poloxamer 407 as carrier were developed to improve albendazole solubility and dissolution profiles. Methodology: Albendazole/Poloxamer solid dispersions were prepared, and dissolution profiles were mathematically modeled and compared with physical mixtures, pharmaceutical albendazole, and a commercial formulation. Results: Poloxamer 407 increased exponentially albendazole solubility, in about 400% when 95% w/w of polymer compared with its absence. Solid dispersions initial dissolution rate was 3 to 20-fold higher than physical mixtures, the drug and the commercial formulation. All the solid dispersions required less than 2.2 min to reach an 80% of albendazole dissolution, while the commercial formulation needed around 40 min. Conclusion: Solid dispersions improved albendazole solubility and dissolution rate, what could result in a faster absorption and an increased bioavailability.